PT453 – Katrin Preller, Ph.D. & Dr. Michael Mithoefer – Neuroplasticity, Individualized Integration, and Psychedelic Medicine – Israel 2024

<p>In this episode, David interviews psychiatrist, main researcher behind the first US Phase II trial of MDMA-assisted psychotherapy, and Senior Medical Director at MAPS Public Benefit Corporation: Dr. Michael Mithoefer; and Research Group Lead at the University of Zurich, and Principal Clinical Biomarker Lead at Boehringer Ingelheim, Katrin Preller, Ph.D.</p> <p>Mithoefer, Preller (and David) are speakers at the upcoming Psychedelic Medicine – Israel, which will now take place July 28 - 31, 2024, in Tel Aviv. They discuss the conference and their current research: Preller's neuroimaging and work with psilocybin for alcohol use disorder, and Mithoefer (likely) being extremely close to seeing the FDA approve MDMA-assisted psychotherapy. He talks about how the therapeutic protocols for MDMA-assisted psychotherapy were created, what it's like to be so close to legalization, and how the next challenges will be accessibility and not minimizing therapy in favor of faster turnover. </p> <p>They discuss neuroplasticity and whether or not it actually translates into something in humans; the concept of performing brain scans before a psychedelic experience to look for trauma biomarkers (and how this could actually result in savings over time); the excitement of seeing clinical work and neuroscience progressing in parallel; why integration frameworks need to be individualized; and the importance of embracing different therapeutic approaches.<br /> <br /> <a href= "https://psychedelicstoday.com/2023/10/20/pt453-katrin-preller-ph-d-dr-michael-mithoefer" target="_blank" rel="noopener">Click here to head to the show notes page</a>.</p>